Q2 2025 · 13F-HR
BAKER BROS. ADVISORS LPholdings as filed
Filed 2025-08-14 · accession 0001104659-25-078573
$10.31B
Reported value
89
Positions
2025-06-30
Period end
The Brief · BAKER BROS. ADVISORS LP · Q2 2025
AI · grounded in 13F
BAKER BROS. ADVISORS LP established a new position in BeOne Medicines Ltd. ONC valued at $2.13B. The fund also initiated a new stake in Incyte Corporation INCY for $2.09B. Additional new positions include ACADIA Pharmaceuticals Inc. ACAD at $925.28M and Insmed Incorporated INSM at $776.23M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 07725L102 | ONC | BeOne Medicines Ltd. | $2.13B | 20.7% | 8,799,053 | Common | SOLE |
| 45337C102 | INCY | Incyte Corporation | $2.09B | 20.3% | 30,743,275 | Common | SOLE |
| 004225108 | ACAD | ACADIA Pharmaceuticals Inc. | $925.3M | 8.98% | 42,896,690 | Common | SOLE |
| 457669307 | INSM | Insmed Incorporated | $776.2M | 7.53% | 7,712,900 | Common | SOLE |
| 86627T108 | SMMT | Summit Therapeutics Inc. | $717.6M | 6.96% | 33,722,974 | Common | SOLE |
| 558868105 | MDGL | Madrigal Pharmaceuticals, Inc. | $598.0M | 5.80% | 1,976,018 | Common | SOLE |
| 76243J105 | RYTM | Rhythm Pharmaceuticals, Inc. | $354.1M | 3.44% | 5,604,483 | Common | SOLE |
| 76155X100 | RVMD | Revolution Medicines, Inc. | $344.5M | 3.34% | 9,364,972 | Common | SOLE |
| 501575104 | KYMR | Kymera Therapeutics, Inc. | $290.3M | 2.82% | 6,651,429 | Common | SOLE |
| G01767105 | ALKS | Alkermes plc | $183.4M | 1.78% | 6,410,603 | Common | SOLE |
| 76029N106 | REPL | Replimune Group, Inc. | $102.6M | 1.00% | 11,045,336 | Common | SOLE |
| 90400D108 | RARE | Ultragenyx Pharmaceutical Inc. | $100.8M | 0.98% | 2,772,692 | Common | SOLE |
| 28036F105 | EWTX | Edgewise Therapeutics, Inc. | $95.8M | 0.93% | 7,305,940 | Common | SOLE |
| 00288U106 | ABCL | AbCellera Biologics Inc. | $94.4M | 0.92% | 27,525,640 | Common | SOLE |
| 45258J102 | IMVT | Immunovant, Inc. | $87.3M | 0.85% | 5,457,881 | Common | SOLE |
| 384747101 | GRAL | GRAIL, Inc. | $83.8M | 0.81% | 1,630,125 | Common | SOLE |
| G52694109 | KNSA | Kiniksa Pharmaceuticals International, plc | $78.2M | 0.76% | 2,824,669 | Common | SOLE |
| 088786108 | BCYC | Bicycle Therapeutics plc | $75.7M | 0.73% | 10,885,357 | Common | SOLE |
| 45258D105 | IMCR | Immunocore Holdings plc | $72.9M | 0.71% | 2,322,656 | Common | SOLE |
| 15102K100 | CELC | Celcuity Inc. | $72.8M | 0.71% | 5,450,445 | Common | SOLE |
| 50015M109 | KOD | Kodiak Sciences Inc. | $64.6M | 0.63% | 17,310,490 | Common | SOLE |
| N44445109 | IMTX | Immatics N.V. | $54.7M | 0.53% | 10,168,901 | Common | SOLE |
| 86150R107 | STOK | Stoke Therapeutics, Inc. | $52.6M | 0.51% | 4,633,838 | Common | SOLE |
| 24823R105 | DNLI | Denali Therapeutics Inc. | $52.2M | 0.51% | 3,731,695 | Common | SOLE |
| 86366E106 | GPCR | Structure Therapeutics Inc. | $52.0M | 0.50% | 2,508,767 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA Biosciences, Inc. | $44.5M | 0.43% | 2,118,728 | Common | SOLE |
| 67080M103 | NRIX | Nurix Therapeutics, Inc. | $44.2M | 0.43% | 3,882,125 | Common | SOLE |
| G76279101 | ROIV | Roivant Sciences Ltd. | $42.5M | 0.41% | 3,767,773 | Common | SOLE |
| 09075V102 | BNTX | BioNTech SE | $39.3M | 0.38% | 368,923 | Common | SOLE |
| 29384C108 | TRDA | Entrada Therapeutics, Inc. | $32.7M | 0.32% | 4,865,819 | Common | SOLE |
| N5749R100 | 2GH | Merus N.V. | $30.2M | 0.29% | 574,377 | Common | SOLE |
| 74006W207 | PRAX | Praxis Precision Medicines, Inc. | $29.0M | 0.28% | 689,488 | Common | SOLE |
| 45826J105 | NTLA | Intellia Therapeutics, Inc. | $25.1M | 0.24% | 2,675,674 | Common | SOLE |
| 92790C104 | VRDN | Viridian Therapeutics, Inc. | $24.4M | 0.24% | 1,744,406 | Common | SOLE |
| 61225M102 | GLUE | Monte Rosa Therapeutics, Inc. | $22.2M | 0.22% | 4,916,095 | Common | SOLE |
| 925050106 | VRNA | Verona Pharma plc | $21.2M | 0.21% | 223,843 | Common | SOLE |
| 92243G108 | PCVX | Vaxcyte, Inc. | $20.8M | 0.20% | 640,885 | Common | SOLE |
| 04016X101 | ARGX | argenx SE | $20.8M | 0.20% | 37,760 | Common | SOLE |
| 92539P101 | — | Verve Therapeutics, Inc. | $19.0M | 0.18% | 1,691,530 | Common | SOLE |
| 157085101 | CERS | Cerus Corporation | $18.2M | 0.18% | 12,883,844 | Common | SOLE |
| 254604101 | IRON | Disc Medicine, Inc. | $17.9M | 0.17% | 337,050 | Common | SOLE |
| 00973Y108 | AKRO | Akero Therapeutics, Inc. | $17.3M | 0.17% | 324,630 | Common | SOLE |
| 09627Y109 | 2655787D | Blueprint Medicines Corporation | $16.1M | 0.16% | 125,538 | Common | SOLE |
| 81749D107 | SERA | Sera Prognostics, Inc. | $15.2M | 0.15% | 5,498,170 | Common | SOLE |
| 04280A100 | ARWR | Arrowhead Pharmaceuticals, Inc. | $14.8M | 0.14% | 939,174 | Common | SOLE |
| 64135M105 | NGNE | Neurogene Inc. | $14.8M | 0.14% | 991,691 | Common | SOLE |
| 252828108 | DNTH | Dianthus Therapeutics, Inc. | $14.7M | 0.14% | 789,759 | Common | SOLE |
| 15117B202 | CLDX | Celldex Therapeutics, Inc. | $13.5M | 0.13% | 665,370 | Common | SOLE |
| 23306J309 | DBVT | DBV Technologies S.A. | $13.4M | 0.13% | 1,461,425 | Common | SOLE |
| 98420N105 | XENE | Xenon Pharmaceuticals Inc. | $11.6M | 0.11% | 370,208 | Common | SOLE |
| 171757206 | CDTX | Cidara Therapeutics, Inc. | $11.1M | 0.11% | 227,272 | Common | SOLE |
| 03940C100 | ACLXGBX | Arcellx, Inc. | $11.0M | 0.11% | 166,825 | Common | SOLE |
| 670703107 | NUVL | Nuvalent, Inc. | $11.0M | 0.11% | 143,937 | Common | SOLE |
| 00773J202 | SYRE | Spyre Therapeutics, Inc. | $9.4M | 0.09% | 626,703 | Common | SOLE |
| 877619106 | TSHA | Taysha Gene Therapies, Inc. | $9.3M | 0.09% | 4,004,756 | Common | SOLE |
| 74065P101 | PRLD | Prelude Therapeutics Inc. | $8.2M | 0.08% | 10,123,824 | Common | SOLE |
| 22663K107 | CRNX | Crinetics Pharmaceuticals, Inc. | $8.1M | 0.08% | 280,000 | Common | SOLE |
| 23284F105 | CTMX | CytomX Therapeutics, Inc. | $7.9M | 0.08% | 3,484,226 | Common | SOLE |
| 786700104 | SGMT | Sagimet Biosciences Inc. | $7.3M | 0.07% | 952,996 | Common | SOLE |
| 829401108 | SION | Sionna Therapeutics, Inc. | $6.9M | 0.07% | 400,000 | Common | SOLE |
| 00847X104 | AGIO | Agios Pharmaceuticals, Inc. | $6.3M | 0.06% | 189,866 | Common | SOLE |
| 75383L102 | RAPP | Rapport Therapeutics, Inc. | $6.3M | 0.06% | 550,090 | Common | SOLE |
| 83086J200 | SKYE | Skye Bioscience, Inc. | $6.1M | 0.06% | 1,450,638 | Common | SOLE |
| 25056L103 | DSGN | Design Therapeutics, Inc. | $5.8M | 0.06% | 1,712,882 | Common | SOLE |
| 483119202 | KALAEUR | KALA BIO, Inc. | $5.7M | 0.06% | 1,201,894 | Common | SOLE |
| 799566104 | SANA | Sana Biotechnology, Inc. | $5.5M | 0.05% | 2,030,949 | Common | SOLE |
| 98401F105 | XNCR | Xencor, Inc. | $5.3M | 0.05% | 670,431 | Common | SOLE |
| 022307102 | ALMS | Alumis Inc. | $4.7M | 0.05% | 1,562,500 | Common | SOLE |
| 449585108 | 1K0 | IGM Biosciences, Inc. | $4.6M | 0.04% | 4,096,210 | Common | SOLE |
| 89854M101 | TCRX | TScan Therapeutics, Inc. | $4.0M | 0.04% | 2,784,792 | Common | SOLE |
| 75943R102 | RLAY | Relay Therapeutics, Inc. | $4.0M | 0.04% | 1,160,117 | Common | SOLE |
| 31189P102 | FATE | Fate Therapeutics, Inc. | $2.8M | 0.03% | 2,485,018 | Common | SOLE |
| 92764N102 | VIR | Vir Biotechnology, Inc. | $2.7M | 0.03% | 542,539 | Common | SOLE |
| 29337E102 | ELVN | Enliven Therapeutics, Inc. | $2.3M | 0.02% | 114,833 | Common | SOLE |
| Y95308105 | WVE | Wave Life Sciences Ltd. | $2.2M | 0.02% | 344,063 | Common | SOLE |
| 878972108 | TECX | Tectonic Therapeutic, Inc. | $2.0M | 0.02% | 100,000 | Common | SOLE |
| 137404109 | CADL | Candel Therapeutics, Inc. | $1.8M | 0.02% | 355,112 | Common | SOLE |
| 74365U107 | TARA | Protara Therapeutics, Inc. | $1.6M | 0.02% | 536,832 | Common | SOLE |
| 918385204 | VTVT | vTv Therapeutics, Inc. | $1.5M | 0.01% | 97,314 | Common | SOLE |
| 77313F106 | RCKT | Rocket Pharmaceuticals, Inc. | $1.4M | 0.01% | 552,079 | Common | SOLE |
| 21217B100 | CTNM | Contineum Therapeutics, Inc. | $1.2M | 0.01% | 312,500 | Common | SOLE |
| 43906K209 | HOOK | HOOKIPA Pharma Inc. | $1.0M | 0.01% | 812,814 | Common | SOLE |
| 640979100 | NMRA | Neumora Therapeutics, Inc. | $758,672 | 0.01% | 1,034,600 | Common | SOLE |
| 37148K100 | GBIOGBX | Generation Bio Co. | $622,577 | 0.01% | 1,944,945 | Common | SOLE |
| 01626L204 | ALGS | Aligos Therapeutics, Inc. | $598,827 | 0.01% | 83,055 | Common | SOLE |
| 90240B106 | TYRA | Tyra Biosciences, Inc. | $101,509 | 0.00% | 10,607 | Common | SOLE |
| 004890109 | ACRV | Acrivon Therapeutics, Inc. | $27,143 | 0.00% | 22,809 | Common | SOLE |
| 86889P117 | SRZNW | Surrozen, Inc. | $15,083 | 0.00% | 833,333 | Common | SOLE |
| 68386J208 | OPTEY | Opthea Limited | $0 | — | 2,087,320 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.